10-K: Hims & Hers Health, Inc. Reports 65% Revenue Growth in 2023, Driven by Subscriber Expansion and New Offerings

Hims & Hers Health, Inc. announced a significant 65% increase in revenue for 2023, reaching $872 million, fueled by a 48% growth in subscribers and successful expansion into new health and wellness specialties.

Summary

• Hims & Hers Health, Inc. reported a 65% increase in total revenue for the year ended December 31, 2023, reaching $872.0 million compared to $526.9 million in 2022.
• Online revenue grew by 68% to $842.4 million, driven by a 48% increase in subscribers, totaling 1.537 million by the end of 2023.
• Wholesale revenue also saw growth, increasing by 21% to $29.6 million.
• The company attributed the growth to increased traffic to its platform, improved customer conversion rates, and the introduction of new product offerings.
• Monthly Online Revenue per Average Subscriber slightly increased by 2% to $54, and Average Order Value (AOV) grew by 18% to $97.
• The company plans to continue investing in growth, including expanding its fulfillment capabilities, enhancing its product offerings, and further developing its mobile applications.
• Hims & Hers is also focusing on expanding into new health and wellness specialties to reach a broader customer base.

Sentiment

Score: 8

Explanation: The document reflects a positive outlook for Hims & Hers, with strong revenue and subscriber growth, expansion into new markets, and a solid financial position. However, the company still faces challenges, including competition and regulatory uncertainties, and is not yet profitable on a net income basis. Overall, the sentiment is positive but with some reservations.

Positives

• The company experienced substantial revenue growth of 65% in 2023, reaching $872.0 million.
• Subscriber base expanded significantly by 48%, reaching 1.537 million by year-end.
• Online revenue, the primary revenue driver, saw a robust 68% increase.
• The company successfully expanded its product offerings and entered new health and wellness specialties.
• Wholesale partnerships contributed to revenue growth and increased brand awareness.
• The company maintains a strong brand reputation and customer loyalty.
• Investments in technology and infrastructure are driving operational efficiencies.
• The company has a strong cash position, with $96.7 million in cash and cash equivalents and $124.3 million in short-term investments as of December 31, 2023.

Negatives

• The company reported a net loss of $23.5 million for 2023, although this was an improvement from the $65.7 million net loss in 2022.
• Marketing expenses remain high, accounting for 51% of total revenue in 2023.
• The company faces intense competition in the telehealth and health and wellness markets.
• The company is subject to a complex and evolving regulatory environment.
• The company's reliance on third-party service providers, such as AWS and Partner Pharmacies, could pose risks to its operations.

Risks

• The company's limited operating history and evolving business model make it difficult to evaluate future prospects.
• Fluctuations in quarterly and annual results may lead to missed expectations.
• Inability to expand offerings, attract and retain customers, or maintain relationships with providers could harm the business.
• Competition from established healthcare providers, retailers, and technology companies may impact market share.
• Failure to maintain brand reputation or comply with regulations could lead to financial and reputational damage.
• Dependence on Affiliated Medical Groups and Pharmacies creates vulnerability to disruptions in these relationships.
• Changes in healthcare regulations, privacy laws, or enforcement activities could increase costs and operational complexity.
• Cybersecurity breaches or data loss could compromise sensitive information and expose the company to liability.
• The company may require additional capital to support growth, which may not be available on acceptable terms.
• The dual-class common stock structure concentrates voting power with the CEO, limiting investor influence.

Future Outlook

The company expects continued growth in the future, driven by investments in marketing, product development, and expansion into new health and wellness specialties. They anticipate leveraging their existing capabilities to penetrate new sales channels and improve operations. However, they also acknowledge potential challenges, including competition, regulatory changes, and the need to manage growth effectively.

Industry Context

The announcement reflects the broader trend of increasing consumer adoption of telehealth and digital health solutions. Hims & Hers is positioned as a leader in the direct-to-consumer healthcare market, which is experiencing rapid growth and attracting new entrants. The company's focus on subscription-based services aligns with the growing popularity of subscription models in various industries.

Comparison to Industry Standards

• Hims & Hers' revenue growth of 65% in 2023 is significantly higher than the average growth rate of the overall telehealth market. For example, Teladoc, a major competitor, reported revenue growth of 18% in 2022. Amwell, another competitor, reported a revenue decline of 11% in 2022.
• The company's subscriber growth of 48% also outpaces many competitors in the space. Teladoc reported a 9% increase in total visits in 2022, while Amwell reported a 1% decrease in total visits.
• Hims & Hers' focus on specific health and wellness verticals, such as sexual health, hair loss, and dermatology, allows it to achieve higher customer lifetime value compared to companies offering a broader range of telehealth services. This is reflected in their higher Average Order Value (AOV) and Monthly Online Revenue per Average Subscriber compared to some competitors.
• Compared to Ro, another direct-to-consumer healthcare company, Hims & Hers has a broader product and service offering and a larger subscriber base. Ro reported revenue of $229.8 million in 2021, significantly lower than Hims & Hers' $872.0 million in 2023.

Related Party Transactions

• The Company recorded a total of $4.6 million, $3.6 million, and $3.5 million for the years ended December 31, 2023, 2022, and 2021, respectively, within operating expenses on the consolidated statements of operations and comprehensive loss for payments made to Terminal, Inc., a related party company that provides professional services to the Company, primarily to support engineering and operations functions.
• In addition, for the years ended December 31, 2023, 2022, and 2021, the Company recorded $2.1 million, $1.0 million, and $0.7 million, respectively, within operating expenses on the consolidated statements of operations and comprehensive loss for payments made to Vouched, a related-party company that provides identity verification services.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to revenue growth and expansion, but also risks associated with competition and regulatory changes.
• Employees: Continued investment in growth may lead to new job opportunities, but also pressure to maintain performance.
• Customers: Expanded product offerings and improved customer experience may enhance value proposition.
• Suppliers: Increased demand for products and services may benefit suppliers.
• Creditors: Strong financial performance and cash position may improve creditworthiness.

Next Steps

• Continue to invest in marketing to acquire new customers.
• Expand product offerings and enhance the customer experience.
• Grow within the existing customer base through longer-term subscription adoption and cross-selling opportunities.
• Pursue specialty expansion into new conditions that can be treated safely and effectively via telehealth.
• Leverage existing capabilities to penetrate new sales channels and further improve operations.
• Expand into new geographies.
• Continue to monitor and adapt to the evolving regulatory landscape.

Key Dates

Keywords

telehealth, digital health, consumer health, wellness, subscription, pharmacy fulfillment, online pharmacy, prescription medication, erectile dysfunction, hair loss, dermatology, mental health, weight loss, e-commerce, direct-to-consumer, healthcare, FDA, HIPAA, CCPA, CPRA, GDPR